📗 Cite This Artifact
Therapeutic Approach Evidence Rankings
Therapeutic Approach Evidence Rankings
Overview
This page synthesizes therapeutic approaches for neurodegenerative diseases, ranking them by clinical evidence strength, mechanism validation, and development pipeline completeness. These rankings integrate data from investment activity, clinical trial outcomes, and mechanistic evidence to identify the most promising therapeutic directions.
Methodology
Ranking criteria:
- Clinical Evidence (0-100): Phase 2/3 trial efficacy signals, biomarker validation, regulatory success
- Mechanism Strength (0-100): Genetic validation, animal model reproducibility, human biomarker correlation
- Pipeline Maturity (0-100): Active programs, programs per phase, recent advancements
- Overall Score: Weighted combination (40% Clinical + 30% Mechanism + 30% Pipeline)
Alzheimer's Disease Therapeutics Rankings
Amyloid-Targeting Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Lecanemab (monoclonal antibody) | 95 | 90 | 85 | 90.5 | Approved |
| 2 | Donanemab (monoclonal antibody) | 90 | 85 | 80 | 85.5 | Approved |
| 3 | Aβ vaccine (ACC-001) | 60 | 80 | 70 | 70.0 | Phase 2 |
| 4 | BACE1 inhibitors (umbrecenestat) | 40 | 70 | 30 | 47.0 | Halted |
| 5 | γ-secretase modulators | 30 | 60 | 40 | 43.0 | Phase 1 |
Therapeutic Approach Evidence Rankings
Overview
This page synthesizes therapeutic approaches for neurodegenerative diseases, ranking them by clinical evidence strength, mechanism validation, and development pipeline completeness. These rankings integrate data from investment activity, clinical trial outcomes, and mechanistic evidence to identify the most promising therapeutic directions.
Methodology
Ranking criteria:
- Clinical Evidence (0-100): Phase 2/3 trial efficacy signals, biomarker validation, regulatory success
- Mechanism Strength (0-100): Genetic validation, animal model reproducibility, human biomarker correlation
- Pipeline Maturity (0-100): Active programs, programs per phase, recent advancements
- Overall Score: Weighted combination (40% Clinical + 30% Mechanism + 30% Pipeline)
Alzheimer's Disease Therapeutics Rankings
Amyloid-Targeting Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Lecanemab (monoclonal antibody) | 95 | 90 | 85 | 90.5 | Approved |
| 2 | Donanemab (monoclonal antibody) | 90 | 85 | 80 | 85.5 | Approved |
| 3 | Aβ vaccine (ACC-001) | 60 | 80 | 70 | 70.0 | Phase 2 |
| 4 | BACE1 inhibitors (umbrecenestat) | 40 | 70 | 30 | 47.0 | Halted |
| 5 | γ-secretase modulators | 30 | 60 | 40 | 43.0 | Phase 1 |
Evidence Synthesis: The approval of lecanemab and donanemab represents an unprecedented validation of the amyloid cascade hypothesis[@van2023]. However, the modest clinical effect size (27% slowing of decline) suggests amyloid clearance alone is insufficient for full disease modification.
Key References:
- [Lecanemab CLARITY-AD Trial (2023)](https://doi.org/10.1056/NEJMoa2212948)
- [Donanemab TRAILBLAZER-ALZ 2 (2023)](https://doi.org/10.1056/NEJMoa2303990)
Tau-Targeting Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Tau immunotherapy (gosuranemab) | 70 | 85 | 75 | 76.5 | Phase 3 |
| 2 | Tau aggregation inhibitors (MCC) | 55 | 75 | 60 | 63.5 | Phase 2 |
| 3 | Tau kinase inhibitors (GSK-3β) | 40 | 65 | 45 | 50.0 | Phase 1 |
| 4 | O-GlcNAcase inhibitors | 35 | 60 | 40 | 45.0 | Phase 1 |
Evidence Synthesis: Tau pathology shows stronger correlation with cognitive decline than amyloid[@murphy2023]. The failure of several tau immunotherapy programs (gosuranemab, semorinemab) has raised questions about tau as a therapeutic target.
Neuroprotective Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | GLP-1 receptor agonists | 75 | 70 | 80 | 75.5 | Phase 3 |
| 2 | Neurotrophic factors (BDNF) | 45 | 80 | 40 | 55.5 | Phase 1 |
| 3 | Anti-oxidative stress | 50 | 65 | 50 | 55.0 | Phase 2 |
| 4 | Metal chelation therapy | 35 | 55 | 30 | 40.5 | Phase 2 |
Evidence Synthesis: GLP-1 agonists (liraglutide, semaglutide) show promise in AD clinical trials with effects on neuroinflammation and synaptic function[@femminella2023].
Parkinson's Disease Therapeutics Rankings
Alpha-Synuclein Targeting
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | α-syn immunotherapy (prasinezumab) | 65 | 80 | 70 | 71.5 | Phase 2 |
| 2 | Small molecule aggregation inhibitors | 50 | 75 | 55 | 60.5 | Phase 1 |
| 3 | Gene therapy (AAV-A53T) | 40 | 70 | 35 | 48.5 | Preclinical |
| 4 | RNA targeting (ASO) | 35 | 65 | 40 | 47.0 | Phase 1 |
Evidence Synthesis: The failure of pasAD and related trials has shifted focus to earlier intervention and biomarker-driven patient selection[@pajares2020].
LRRK2-Targeting Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | LRRK2 kinase inhibitors (DNL151) | 60 | 85 | 65 | 70.5 | Phase 2 |
| 2 | LRRK2 ASO therapy | 40 | 70 | 45 | 52.0 | Phase 1 |
| 3 | LRRK2 gene editing | 25 | 55 | 20 | 34.0 | Preclinical |
Evidence Synthesis: LRRK2 inhibitors show promise in PD, with genetic validation from G2019S mutation[@cook2023]. However, the role of LRRK2 in sporadic PD remains unclear.
Mitochondrial/Autophagy Enhancement
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | TFEB activators | 45 | 75 | 55 | 58.5 | Phase 1 |
| 2 | Mitophagy enhancers (urolithin A) | 55 | 70 | 60 | 61.5 | Phase 3 |
| 3 | CoQ10 supplementation | 50 | 60 | 45 | 52.0 | Phase 3 |
| 4 | PINK1/Parkin activators | 30 | 65 | 25 | 40.5 | Preclinical |
Evidence Synthesis: Mitochondrial dysfunction is a central mechanism in PD, but clinical translation has been challenging[@borsche2021].
ALS Therapeutics Rankings
Gene-Targeting Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Tofersen (SOD1 ASO) | 85 | 95 | 80 | 87.0 | Approved |
| 2 | C9orf72 ASO | 65 | 90 | 60 | 72.0 | Phase 3 |
| 3 | FUS gene therapy | 45 | 75 | 40 | 54.0 | Phase 1 |
| 4 | ATXN2 ASO | 50 | 70 | 45 | 55.5 | Phase 1 |
Evidence Synthesis: Tofersen approval validates gene-targeting approaches in ALS[@miller2023]. The challenge remains that by the time symptoms appear, significant neuronal loss has already occurred.
Neuroprotective Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Riluzole (glutamate modulation) | 70 | 55 | 60 | 62.5 | Approved |
| 2 | Edaravone (anti-oxidant) | 65 | 50 | 55 | 57.5 | Approved |
| 3 | Antisense SOD1 gene therapy | 80 | 90 | 75 | 82.0 | Approved |
| 4 | Stem cell therapy | 35 | 60 | 30 | 42.0 | Phase 1 |
Cross-Disease Mechanism Rankings
Neuroinflammation Modulation
| Rank | Mechanism | AD Score | PD Score | ALS Score | Avg | Priority |
|------|-----------|----------|----------|-----------|-----|----------|
| 1 | TREM2 modulation | 80 | 70 | 60 | 70 | High |
| 2 | NLRP3 inhibition | 65 | 70 | 65 | 67 | High |
| 3 | CSF1R blockade | 60 | 55 | 70 | 62 | Medium |
| 4 | Complement inhibition | 55 | 50 | 60 | 55 | Medium |
Evidence Synthesis: Microglial modulation represents a promising cross-disease approach, particularly TREM2 variants showing strong AD genetic validation[@deczkowska2023].
Protein Homeostasis
| Rank | Mechanism | AD Score | PD Score | ALS Score | Avg | Priority |
|------|-----------|----------|----------|-----------|-----|----------|
| 1 | Autophagy induction (TFEB) | 70 | 75 | 65 | 70 | High |
| 2 | Proteasome enhancement | 55 | 60 | 70 | 62 | Medium |
| 3 | Chaperone modulation | 50 | 65 | 60 | 58 | Medium |
| 4 | Unfolded protein response | 45 | 50 | 55 | 50 | Low |
Investment Signal Synthesis
Based on pipeline activity, clinical success rates, and mechanism validation:
Highest Priority Investment Themes
Emerging Themes Requiring Further Validation
Causal Chain Examples
AD Amyloid Hypothesis Causal Chain
PD LRRK2 Pathway Causal Chain
Knowledge Gaps and Research Priorities
AD Priority Gaps
PD Priority Gaps
See Also
- Investment Rankings
- [Therapeutic Targetability Rankings](/mechanisms/therapeutic-targetability-rankings)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- Parkinson's Disease Pathway
- [ALS Pathway](/mechanisms/als-pathway)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-therapeutic-approach-evidence-rankings |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-8796094dae4a |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-therapeutic-approach-evidence-rankings'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-therapeutic-approach-evidence-rankings?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Therapeutic Approach Evidence Rankings](http://scidex.ai/artifact/wiki-mechanisms-therapeutic-approach-evidence-rankings)
http://scidex.ai/artifact/wiki-mechanisms-therapeutic-approach-evidence-rankings